The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Biz Plan Competition | Alive

Total Raised


Last Raised

$10K | 2 yrs ago

About Axentless

Axentless is a software using advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims.

Axentless Headquarter Location


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Axentless

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Axentless is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,454 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Latest Axentless News

Startups developing novel therapeutics in oncology, a software for interactive speech therapy, solutions for reliable machine learning, a personalized surgical plan for complex traumas, and a data-based platform for energy providers each win CHF 10,000

Jun 24, 2020

22.06.2020 ABOLOGIX, Axentless, Calicarpa, CustomSurg, and Exnaton Teams win Venture Kick’s financial and entrepreneurial support. Their projects increase overall survival of lymphoma patients, use advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims, develop software solutions for emerging reliability issues in Machine Learning, help energy providers becoming services providers in a liberalized energy market. ABOLOGIX's Founders: Ignacio Faus, Beat Imhof and Thomas Matthes Axentless' Founder Amjad Mallisho Calicarpa's Founders: (from left to right) Lê Nguyên Hoang, Sébastien Rouault, El Mahdi El Mahmdi CustomSurg: Valentin Splett Chief Business Officer, co-inventors Thomas Zumbrunn CEO / Chief Innovation Officer and Dr. med. Arvind von Keudell Exnaton's CEO Liliane Ableitner, CTO Arne Meeuw and CXO Anselma Wörner ABOLOGIX: increasing overall survival of lymphoma patients B-cell lymphocytes play a critical role in the fight against infections and cancer. But these cells can become cancerous and transform into white blood cell cancers called lymphomas, leading, in many cases, to death. Most available therapies show efficacy in the early stages of treatment. Unfortunately, patients usually become resistant to these therapies and eventually die. ABOLOGIX, a biopharmaceutical company based in Geneva and spin-out from the laboratories at the University of Geneva, is developing a new therapeutic option to serve lymphoma patients. The founders of the company are Dr. Ignacio Faus, a successful entrepreneur with more than 20 years of management experience in the pharma and biotech industries, Dr. Beat Imhof, Professor at the University of Geneva, the leading expert in the field of JAM-C biochemistry/immunology, and Dr. Thomas Matthes, a physician at the University of Geneva Hospitals with a specialty in hematological cancers. The company´s lead program is a monoclonal antibody (code-named H-225) for the treatment of several sub-types of non-Hodgkin´s lymphoma (NHL), specifically Mantle Cell Lymphoma (MCL), a disease of very poor prognosis. H-225 blocks the function of JAM-C, a cell adhesion molecule involved in the transmigration of lymphocytes out of the tissues and into the bloodstream. In preclinical in vivo animal models ABOLOGIX has shown that treatment with H-225 leads to a dramatic increase in overall survival. The next steps are the humanization of H-225 (in progress) and testing the potential of the molecule in Phase I/IIa clinical trials. They then intend to license/sell H-225 to a large pharma company for further development and commercialization. The expected market potential in 2024 for the treatment of drug-resistant blood cancers is of the order of 20 billion USD. The Venture Kick funds will first be used for a market research study and to refine and improve the development plan of the molecule. Axentless: software automating speech therapy home practice Axentless is a software using advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims. A lot of stroke patients lose their ability to speak and communicate. They often go through several months of intensive speech therapy which doesn't always include aided home practice. Meaning the patient nor therapist has a consistent way to track progress and keep the patient motivated at home. Axentless’ Founder, Dr. Amjad Mallisho, M.D. at Reha Rheinfelden develops a software application for smartphones and tablets that stroke patients can use to support home therapy practice. Thanks to advanced algorithmic technologies, the app helps them stay motivated by giving them interactive feedback to improve, tracking their progress and helps build their confidence. Patients get tailored, customized feedback based on their personal performance compared to the standard. It's an interactive and engaging training experience that they target to Rehab Clinics and individual patients who suffer a stroke or other speech impairment disorders. They plan to use Venture Kick funds to support their marketing activities and make Axentless market-ready in Switzerland. Calicarpa: Reliable Machine learning Calicarpa develops software solutions for emerging reliability issues in machine learning (ML) / artificial intelligence (AI) applications. The three co-founders, El Mahdi El Mahmdi, Sébastien Rouault (both PhDs at EPFL) and Lê Nguyên Hoang have filled one patent on ML reliability and security and are in the process of filling another one for ML privacy. Their asset consists of a portfolio of algorithms, software plugins for the two major ML frameworks (Facebook's PyTorch and Google's TensorFlow), and other standalone software solutions of their own. One of Calicarpa's solutions is now used by WeBank, the first digital-only bank in China. They first aim at licensing their existing and future patented software solutions which are agnostic to the ML task of the customer and are already integrated with the two major ML frameworks. This will help social networking websites facing a lot of mislabeled data better avoid fake news for example. For smaller clients, such as local or national news websites, Calicarpa will offer in-house robust content recommendations. Finally, for bigger corporate clients, they will develop tailored solutions, integrating prior business knowledge of the customer into the software, and target additional frameworks. In the next three months, Calicarpa team plans to use Venture Kick funds to incorporate, prepare business meetings with telecommunication companies, and approach more potential partners in the banking and social network fields. CustomSurg: Personalized solutions in complex trauma surgery Bone fractures involving a joint are complex in nature, causing difficult and time-consuming procedures for treating orthopedic surgeons with several hours of occupation of the operating room. CustomSurg, developed by co-inventors Dr. sc. Thomas Zumbrunn (ETH Zurich), Dr. med. Arvind von Keudell (Harvard Medical School), and commercial strategist Valentin Splett, optimizes complex bone reconstruction and could significantly reduce the duration of surgery. CustomSurg provides personalized solutions in complex trauma surgery, based on a proprietary process. They propose biomechanical optimization of surgical planning as well as implant and instrument design, based on case-specific fracture patterns. This could improve patient outcomes through better fracture stability and reduced impact (invasiveness) during surgery. The product-service bundle, consisting of a personalized surgical plan together with patient-specific implants and instrument design, is sold to hospitals and surgeons via a made-to-order model. The use of this technology could improve quality of life for 400’000 annual trauma patients, capturing part of a $1.2 billion market. They now have an existing implant prototype that was designed using the basic version of the simulation. A patent application is in submission through ETH transfer. The funds from stage one will be used for in-depth quantitative market research through a larger number of surveys with surgeons and hospital administrators. Exnaton: bringing the sharing economy to the energy sector Digitalization, decarbonization, and decentralization transform the role of energy providers from being retailers in a regulated market to becoming service providers in a liberalized energy market (planned for 2023). For instance, energy providers have to equip end-users with smart meters and provide data visualization until 2027. The good news is that innovative software and data services can not only help them build up a better customer relationship to prevent churn, but also to digitize internal processes or even to create new revenue streams. With its platform of data-based services, Exnaton offers software for energy providers. The base product offers a tangible user experience with a customer portal and the possibility to buy solar electricity from neighbors (=local energy market). Further data-based services such as storage renting models or flexibility control are planned for the future. The team composed of CEO Liliane Ableitner, CTO Arne Meeuw, and CXO Anselma Wörner, launched their prototype in the Quartierstrom research project during their PhDs at ETHZ and HSG. Due to enthusiastic user reactions, their current goal is to serve additional energy providers with a software product in SaaS revenue models. The Venture Kick funds will mainly be used for refining the problem-solution fit with customer feedback, to win further pilot projects, and to participate at domain-specific energy events. Additional Links

  • What is Axentless's latest funding round?

    Axentless's latest funding round is Biz Plan Competition.

  • How much did Axentless raise?

    Axentless raised a total of $10K.

  • Who are the investors of Axentless?

    Investors of Axentless include Venture Kick.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.